<DOC>
	<DOCNO>NCT02757326</DOCNO>
	<brief_summary>This Phase Ib/II safety efficacy trial single agent ABC294640 , inhibitor sphingosine kinase 2 dihydroceramide desaturase , refractory relapse multiple myeloma ( MM ) . Cohorts patient refractory relapse MM previously treat proteasome inhibitor immunomodulatory agent receive increase dos oral ABC294640 . The starting dosage ABC294640 250 mg bi die ( BID ) know safely tolerate single agent , ABC294640 dose escalate two additional dose cohort 500 750 mg BID use Bayesian model average continual reassessment method ( BMA-CRM ) dose find . It expect 18 patient used determine maximum tolerate dose ( MTD ) ABC294640 refractory relapse MM . Up 56 additional patient treat phase II portion study MTD maximum dose use phase I , interim stopping rule futility . Pharmacokinetic ( PK ) pharmacodynamic ( PD ) assessments ABC294640 conduct Day 1 Cycle 1 . Bone marrow biopsy obtain prior initiation ABC294640 , end cycle # 3 end cycle # 6 . In addition serum protein electrophoresis ( SPEP ) , urine protein electrophoresis ( UPEP ) serum free light chain measurement , correlative study perform measure sphingosine kinase 2 ( SK2 ) activity , sphingosine metabolite , additional biomarkers CD138+ myeloma cell .</brief_summary>
	<brief_title>ABC294640 Refractory / Relapsed Multiple Myeloma</brief_title>
	<detailed_description>Objectives Phase 1b : Primary Objectives • To assess safety determine maximum tolerate dose ( MTD ) single agent ABC294640 patient refractory relapse multiple myeloma ( MM ) previously treat proteasome inhibitor immunomodulatory agent . Secondary Objectives - To assess antitumor activity single agent ABC294640 patient refractory relapse MM 3 cycle treatment . - To determine pharmacokinetics ABC294640 follow administration drug . - To describe effect ABC294640 plasma level sphingosine 1-phosphate IL-6 patient refractory relapse MM . - To assess pharmacodynamic marker ( SK2 mRNA level activity , sphingolipid metabolite , c-Myc , Mcl-1 pS6 ) bone marrow CD138+ myeloma cell . Objectives Phase 2 : Primary Objectives • Assess overall treatment response rate overall survival patient relapse refractory MM treat single-agent ABC294640 . Secondary Objectives - To assess treatment response ABC294640 patient refractory relapse MM 3 cycle treatment . - To determine pharmacodynamic marker ( SK2 mRNA activity , sphingolipid metabolite , c-Myc , Mcl-1 pS6 ) bone marrow CD138+ myeloma cell predict tumor response treatment ABC294640 . The projected ABC294640 dose escalation phase : 250 , 500 , 750 mg BID orally continuously determine single agent trial ABC294640 . The dose give fasting condition ( least 1 hour 2 hour eat ) . Each cycle treatment 28 day . Patients monitor safety pharmacodynamics effect weekly Cycle 1 , biweekly Cycles 2-4 , monthly subsequent cycle . Myeloma treatment response assess follow : - Serum protein electrophoresis ( SPEP ) , urine protein electrophoresis ( UPEP ) serum free light chain cycle . - Skeletal survey screening , every year end study study end anniversary . - Bone marrow biopsy aspirate last day cycle # 3 cycle # 6 ( ± 7 day ) . For phase II portion study , patient treat single agent ABC294640 MTD determine phase Ib study ( high dose use , MTD reach ) disease progression intolerable toxicity occur .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Patient must diagnosis symptomatic multiple myeloma , relapse refractory previous treatment proteasome inhibitor ( bortezomib carfilzomib ) immunomodulatory agent ( thalidomide , lenalidomide pomalidomide ) . 2 . Have measurable disease define least one following : Serum monoclonal ( M ) protein ≥1.0 g/dl protein electrophoresis &gt; 200 mg M protein urine 24 hour electrophoresis Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥30 % 3 . Voluntary sign dated institutional review board ( IRB ) approve informed consent form accordance regulatory institutional guideline . 4 . Time interval last systemic chemotherapy ( include low dose dexamethasone ) 2 week prior initiation ABC294640 . Patients receive high dose dexamethasone define 40mg dexamethasone day 4 day need 2 week washout prior initiation ABC294640 5 . 18 year age old . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 7 . Acceptable liver function : Bilirubin ≤ 1.5 time upper limit normal ( CTCAE Grade 1 baseline ) AST ( SGOT ) , ALT ( SGPT ) ≤ 5 x ULN ( CTCAE Grade 2 baseline ) Serum creatinine ≤1.5 XULN ( CTCAE Grade 1 baseline ) 8 . Acceptable hematologic status ( without transfusion support ) : Absolute neutrophil count ≥1000 cells/mm3 , Platelet count ≥50,000 ( plt/mm3 ) , Hemoglobin ≥9 g/dL . 9 . Urinalysis : No clinically significant abnormality . 10 . PT PTT ≤ 1.5 X ULN correction nutritional deficiency may contribute prolonged PT/PTT . 11 . As determined treat investigator , patient must wellcontrolled blood pressure , define systolic blood pressure &lt; 150mmHg and/or diastolic blood pressure &lt; 100 mmHg majority measurement . 12 . A negative pregnancy test ( female child bear potential ) . 13 . For men woman childproducing potential , willingness use effective contraceptive method study . 1 . Pregnant nursing woman . 2 . Patients currently participate clinical trial investigational product . 3 . Major surgery within 30 day prior start treatment 4 . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior start treatment 5 . Known human immunodeficiency virus infection 6 . Active hepatitis B C infection abnormal liver function ( i.e. , LFTs &gt; 2 x upper normal limit ) 7 . Unstable angina myocardial infarction within 4 month prior start treatment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker 8 . Uncontrolled hypertension uncontrolled diabetes within 14 day prior start treatment 9 . Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder 10 . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior initiation ABC294640 11 . Any clinically significant medical psychiatric disease condition , social situation , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>sphingosine kinase 2 inhibitor</keyword>
	<keyword>sphingosine kinase 2</keyword>
	<keyword>SK2 inhibitor</keyword>
	<keyword>SK2</keyword>
</DOC>